Prevalence of Fibromyalgia in Israel

Fibromyalgia Clinical Trial

Official title:

Prevalence of Fibromyalgia in Israel

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01203865
• Other study ID #: 0303-10-TLV
• Secondary ID: WS573984
• Status: Recruiting
• Phase: N/A
• First received: September 15, 2010
• Last updated: October 10, 2011
• Start date: October 2010
• Est. completion date: March 2012

Study information

• Verified date: October 2011
• Source: Tel-Aviv Sourasky Medical Center
• Contact: Jacob N Ablin, MD
• Phone: 972-3-6973668
• Email: jacobab[@]tasmc.health.gov.il
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Observational

Clinical Trial Summary

The prevalence of fibromyalgia syndrome in the Israeli population is of importance fro planning resource allocation of medical expenditure as well as for identifying demographic and ethnic differences of this unique population compared with other western samples. In the current study the investigators aim at estimating the prevalence of fibromyalgia in this population. For this purpose a two - stage process will be used. First, a population survey will be conducted by telephone, screening for widespread pain and fatigue in the general population. This survey will use the London Fibromyalgia Epidemiology Study Screening Questionnaire. Second, a sample of patients attending the rheumatology clinic will be surveyed with this tool and will be examined in order to determine the actual proportion of patients fulfilling ACR criteria for fibromyalgia. This will enable us to calculate the positive predictive value of the London Fibromyalgia Epidemiology Study Screening Questionnaire in our population and hence to calculate the prevalence of fibromyalgia in the population.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1200
• Est. completion date: March 2012
• Est. primary completion date: November 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Individuals over 18 who consent to answer the survey questions

Study Design

N/A

Related Conditions & MeSH terms

• Fibromyalgia
• Myofascial Pain Syndromes

Locations

Country	Name	City	State
Israel	Tel Aviv SOurasky Medical center	Tel Aviv

Sponsors (2)

Lead Sponsor	Collaborator
Tel-Aviv Sourasky Medical Center	Pfizer

Country where clinical trial is conducted

Israel, 

References & Publications (1)

Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, Saraiva F, Nacci F, Thomas E, Caubère JP, Le Lay K, Taieb C, Matucci-Cerinic M. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum. 2010 Jun;39(6):448-53. doi: 10.1016/j.semarthrit.2008.12.003. Epub 2009 Feb 27. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of fibromyalgia in the Israeli population		9 months	No
Secondary	Demographic data on fibromyalgia patients		9 months	No